The technology, designed to assist people with conditions such as spinal cord injuries, has already allowed the first patient to play video games, browse the internet, post on social media, and move a cursor on a laptop using thought alone.
Neuralink began human trials in 2024 after addressing safety concerns raised by the U.S. Food and Drug Administration, which had initially rejected its application in 2022. In September, the company reported that 12 individuals worldwide with severe paralysis had received the implants, using them to control both digital and physical tools through brain signals.
The company has also strengthened its financial position, securing $650 million in a funding round in June, a step seen by analysts as crucial to scaling production and advancing its clinical program.
A Neuralink spokesperson did not immediately respond to a request for comment.